UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2024
Commission File Number: 001-41670
Apollomics Inc.
(Translation of registrant’s name into English)
989 E. Hillsdale Blvd., Suite 220
Foster City, CA 94404
Telephone: (650) 209-4055
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
On March 28, 2024, Apollomics Inc. issued a press release titled “Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results.” A copy of this press release is furnished as Exhibit 99.1 herewith.
EXHIBIT INDEX
Exhibit No. |
|
Description |
99.1 |
|
Press release titled “Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results” (furnished herewith) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Apollomics Inc. |
||
Date: March 28, 2024 |
By: |
/s/ Guo-Liang Yu |
|
|
|
Name |
Guo-Liang Yu, Ph.D. |
|
|
Title: |
Chief Executive Officer |